AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12088694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity assessment (PIA) condition with CO(2) laser stimuli of 40ms duration
Number of subjects: 12
Study 12088694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity assessment (PIA) condition with CO(2) laser stimuli of 60ms duration
Number of subjects: 12
Study 12088694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity assessment (PIA) condition with CO(2) laser stimuli of 80ms duration
Number of subjects: 12
Study 12088694 — intervention group
Group type: COMPARATOR
Intervention: Control motor task condition (midpoint of VAS line)
Number of subjects: 12
Study 12088694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity assessment-related potential (IAP) under PIA condition
Number of subjects: 12
Study 9775843 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 14
Study 9775843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7599345 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g bid sucralfate gel
Number of subjects: 368
Study 7599345 — intervention group
Group type: COMPARATOR
Intervention: 1 g qid sucralfate suspension
Number of subjects: 368
Study 3334108 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 375 mg twice daily
Number of subjects: 586
Study 3334108 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 750 mg twice daily
Number of subjects: 586
Study 30775427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY) 25 mcg twice daily
Number of subjects: 2379
Study 30775427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY) 50 mcg twice daily
Number of subjects: 2379
Study 30775427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2379
Study 30775427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY)
Number of subjects: 2379
Study 30775427 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (TIO; 18 mcg once daily)
Number of subjects: 2379
Study 30775427 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 2379
Study 27609033 — intervention group
Group type: EXPERIMENTAL
Intervention: sWBV (side-alternating whole body vibration) for 14 weeks with ten 9-minute sessions weekly
Number of subjects: 24
Study 27609033 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sWBV)
Number of subjects: 24
Study 26304875 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record‐based trigger algorithms for colorectal cancer
Number of subjects: 72
Study 26304875 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record‐based trigger algorithms for prostate cancer
Number of subjects: 72
Study 26304875 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record‐based trigger algorithms for lung cancer
Number of subjects: 72
Study 26304875 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record‐based trigger algorithms
Number of subjects: 72
Study 23122184 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated portable device (APD) for measuring toe-brachial index (TBI)
Number of subjects: 204
Study 23122184 — intervention group
Group type: COMPARATOR
Intervention: Strain-gauge plethysmography (SGP)
Number of subjects: 204
Study 23122184 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of absolute toe pressures
Number of subjects: 204
Study 21358492 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie method
Number of subjects: 350
Study 21358492 — intervention group
Group type: COMPARATOR
Intervention: Manipulation
Number of subjects: 350
Study 18231720 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF)
Number of subjects: 139
Study 18231720 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin/sulbactam (AMP/SUL)
Number of subjects: 139
Study 16572920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg test formulation
Number of subjects: 0
Study 16572920 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 0
Study 12473421 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based exercise (supervised sessions for 6 months)
Number of subjects: 126
Study 12473421 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based exercise
Number of subjects: 126
Study 12473421 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 126
Study 12473421 — intervention group
Group type: COMPARATOR
Intervention: Moderate vs vigorous exercise
Number of subjects: 126
Study 11166091 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 12
Study 11166091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9117837 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary integrated community and hospital leg ulcer service
Number of subjects: 0
Study 7914759 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA enemas (4g/100ml)
Number of subjects: 31
Study 7914759 — intervention group
Group type: COMPARATOR
Intervention: Oral sulphasalazine (2g/day)
Number of subjects: 31
Study 3053176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose warfarin (mean daily dose of 4.6 mg)
Number of subjects: 0
Study 3053176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose warfarin
Number of subjects: 0
Study 31715671 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT‐ERAS intervention
Number of subjects: 572
Study 29072166 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein rich meal during each treatment in the intervention group (IG)
Number of subjects: 99
Study 29072166 — intervention group
Group type: COMPARATOR
Intervention: Usual snack brought from home in the control group (CG)
Number of subjects: 99
Study 29072166 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 99
Study 23380567 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily for 4 weeks
Number of subjects: 33
Study 23380567 — intervention group
Group type: COMPARATOR
Intervention: Quinapril 20 mg daily for 4 weeks
Number of subjects: 33
Study 22477032 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib with cryotherapy (cryoRx)
Number of subjects: 104
Study 22477032 — intervention group
Group type: COMPARATOR
Intervention: sorafenib
Number of subjects: 104
Study 20156334 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytalgic (food supplement containing fish oils, urtica dioica, zinc, and vitamin E)
Number of subjects: 0
Study 20156334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18050198 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 82
Study 18050198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 16286607 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 193
Study 12048081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track extubation protocol
Number of subjects: 323
Study 12048081 — intervention group
Group type: COMPARATOR
Intervention: Non-fast track extubation protocol
Number of subjects: 323
Study 10383925 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dose of 500 mg bosentan (3.7 MBq)
Number of subjects: 8
Study 10383925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dose of 250 mg bosentan (3.7 MBq)
Number of subjects: 8
Study 7801178 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2679831 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 35 mg
Number of subjects: 24
Study 2679831 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 10 mg
Number of subjects: 24
Study 2679831 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 2679831 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam (both doses)
Number of subjects: 24
Study 9125 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxypertine 20 mg orally as a nocturnal sedative and again on the morning of operation
Number of subjects: 185
Study 9125 — intervention group
Group type: COMPARATOR
Intervention: Papaveretum 10 mg
Number of subjects: 185
Study 9125 — intervention group
Group type: COMPARATOR
Intervention: Atropine 0.6 mg
Number of subjects: 185
Study 31283046 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 1981
Study 31283046 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who recovered from stunting
Number of subjects: 1981
Study 31283046 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys born small for gestational age
Number of subjects: 1981
Study 31283046 — intervention group
Group type: COMPARATOR
Intervention: Girls small or appropriate for gestational age at birth
Number of subjects: 1981
Study 31092024 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural oxycodone (EPI group; n = 18)
Number of subjects: 30
Study 31092024 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxycodone (IV group; n = 12)
Number of subjects: 30
Study 28692172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 100,000 IU monthly
Number of subjects: 452
Study 28692172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study 28692172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 100,000 IU monthly (with baseline 25-hydroxyvitamin D ≤ 30 nmol L-1)
Number of subjects: 452
Study 28692172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 100,000 IU monthly (with baseline 25-hydroxyvitamin D > 30 nmol L-1)
Number of subjects: 452
Study 25090099 — intervention group
Group type: EXPERIMENTAL
Intervention: Affectionate interaction
Number of subjects: 60
Study 25090099 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest with the friend/romantic partner present
Number of subjects: 60
Study 25090099 — intervention group
Group type: COMPARATOR
Intervention: Separation from the friend/romantic partner
Number of subjects: 60
Study 23437781 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Bipolar (EBP) configuration
Number of subjects: 50
Study 23437781 — intervention group
Group type: COMPARATOR
Intervention: True Bipolar (TBP) configuration
Number of subjects: 50
Study 22043677 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Sanyinjiao (SP 6)
Number of subjects: 60
Study 22043677 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint group
Number of subjects: 60
Study 22043677 — intervention group
Group type: COMPARATOR
Intervention: Blank group
Number of subjects: 60
Study 19688625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy‐based computer assisted technique
Number of subjects: 0
Study 19688625 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopic technique
Number of subjects: 0
Study 16978160 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 60
Study 16978160 — intervention group
Group type: COMPARATOR
Intervention: No epidural analgesia
Number of subjects: 60
Study 14622056 — intervention group
Group type: EXPERIMENTAL
Intervention: Study item repetition
Number of subjects: 0
Study 14622056 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic similarity
Number of subjects: 0
Study 14622056 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthographic similarity
Number of subjects: 0
Study 14622056 — intervention group
Group type: EXPERIMENTAL
Intervention: Category length
Number of subjects: 0
Study 14622056 — intervention group
Group type: COMPARATOR
Intervention: Massed study time
Number of subjects: 0
Study 10936668 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg three times daily)
Number of subjects: 152
Study 10936668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 9078197 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1486
Study 9078197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1486
Study 8470626 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole plus 4 x 500 mg amoxicillin suspension for 1 wk (group I, n = 35)
Number of subjects: 180
Study 8470626 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 40 mg omeprazole plus 4 x 500 mg amoxicillin for 1 wk (group II, n = 50)
Number of subjects: 180
Study 8470626 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 20 mg omeprazole plus 4 x 500 mg amoxicillin for 2 wk (group III, n = 62)
Number of subjects: 180
Study 8470626 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 20 mg omeprazole (day 1‐14) and 4 x 500 mg amoxicillin (day 8‐14) (group IV, n = 22)
Number of subjects: 180
Study 8470626 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 20 mg omeprazole for 2 wk (group V, n = 11)
Number of subjects: 180
Study 3512149 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nalbuphine
Number of subjects: 128
Study 3512149 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg acetaminophen
Number of subjects: 128
Study 3512149 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nalbuphine and acetaminophen
Number of subjects: 128
Study 3512149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 29337024 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention (n=75)
Number of subjects: 163
Study 29337024 — intervention group
Group type: COMPARATOR
Intervention: MS education intervention (n=88)
Number of subjects: 163
Study 26967465 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-magnitude, high-frequency mechanical stimulation (0.3 g; 32-37 Hz) for 2 sessions lasting 10 minutes each, 7 days per week for 1 year.
Number of subjects: 65
Study 26967465 — intervention group
Group type: COMPARATOR
Intervention: Placebo device used at home.
Number of subjects: 65
Study 24973176 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal esophagoscopy (TNE)
Number of subjects: 184
Study 24973176 — intervention group
Group type: COMPARATOR
Intervention: Esophageal capsule esophagoscopy (ECE)
Number of subjects: 184
Study 22616061 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple zygomatic implants (Zyg); 28 zygomatic and 5 standard implants placed.
Number of subjects: 14
Study 22616061 — intervention group
Group type: COMPARATOR
Intervention: Standard implants (Stand); 41 standard implants placed, 3 lost.
Number of subjects: 14
Study 20640365 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral balanced occlusion
Number of subjects: 24
Study 20640365 — intervention group
Group type: COMPARATOR
Intervention: Canine guidance
Number of subjects: 24
Study 18328120 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 261
Study 18328120 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 261
Study 18328120 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg/HCTZ 12.5 mg
Number of subjects: 261
Study 18328120 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg/HCTZ 25 mg
Number of subjects: 261
Study 18328120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 15818078 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-conditioning group
Number of subjects: 4
Study 15818078 — intervention group
Group type: EXPERIMENTAL
Intervention: Down-conditioning group
Number of subjects: 4
Study 15818078 — intervention group
Group type: COMPARATOR
Intervention: At-random conditioning group
Number of subjects: 4
Study 15818078 — intervention group
Group type: COMPARATOR
Intervention: No-feedback control group
Number of subjects: 4
Study 15818078 — intervention group
Group type: EXPERIMENTAL
Intervention: N150-P260 pain (event)-related potentials
Number of subjects: 4
Study 12006795 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 30
Study 12006795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10584979 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole
Number of subjects: 16
Study 10584979 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg omeprazole
Number of subjects: 16
Study 10584979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8914501 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory stepping responses to unpredictable postural perturbations in elderly subjects
Number of subjects: 14
Study 8914501 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory stepping responses to unpredictable postural perturbations in young subjects
Number of subjects: 14
Study 8914501 — intervention group
Group type: COMPARATOR
Intervention: Comparison of anticipatory postural adjustments between elderly and young subjects
Number of subjects: 14
Study 1862209 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of fluphenazine decanoate (5 to 10 mg every 2 weeks)
Number of subjects: 50
Study 1862209 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious‐Depression subscale of the Brief Psychiatric Rating Scale (BPRS)
Number of subjects: 50
Study 1862209 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of the patient self‐report Early Signs Questionnaire
Number of subjects: 50
Study 1862209 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiosyncratic Prodromal Scale (IPS)
Number of subjects: 50
Study 6352658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 0.5 g every 12 h for 7 to 10 days
Number of subjects: 51
Study 6352658 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 1 mg/kg every 8 h for 7 to 10 days
Number of subjects: 51
Study 30985537 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (pressure applied for 6 minutes, three times a day for a maximum of 2 postoperative days)
Number of subjects: 163
Study 30985537 — intervention group
Group type: COMPARATOR
Intervention: Sham (extremely light touch applied to acupoints)
Number of subjects: 163
Study 30985537 — intervention group
Group type: COMPARATOR
Intervention: No intervention (no touch)
Number of subjects: 163
Study 30985537 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 163
Study 30985537 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 163
Study 30985537 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 163
Study 27816497 — intervention group
Group type: EXPERIMENTAL
Intervention: LR + IND
Number of subjects: 192
Study 27816497 — intervention group
Group type: COMPARATOR
Intervention: NS + placebo
Number of subjects: 192
Study 27816497 — intervention group
Group type: EXPERIMENTAL
Intervention: NS + IND
Number of subjects: 192
Study 26391457 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus non-invasive vagus nerve stimulation (nVNS)
Number of subjects: 97
Study 26391457 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone (control)
Number of subjects: 97
Study 24962473 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 30 mg loading dose on day 1 followed by 10 mg once daily for 3 days
Number of subjects: 12
Study 24962473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg three times a day for 3 days and a single 20 mg dose on day 4
Number of subjects: 12
Study 24962473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both macitentan and sildenafil concomitantly
Number of subjects: 12
Study 21350044 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg oral nicotine lozenge
Number of subjects: 40
Study 21350044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19643672 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate monotherapy
Number of subjects: 406
Study 17333521 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release oxybutynin 10 mg once daily
Number of subjects: 576
Study 17333521 — intervention group
Group type: COMPARATOR
Intervention: Extended-release tolterodine 4 mg once daily
Number of subjects: 576
Study 17333521 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release tolterodine 2 mg twice daily
Number of subjects: 576
Study 15554600 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg for six months
Number of subjects: 41
Study 15554600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11559213 — intervention group
Group type: EXPERIMENTAL
Intervention: Octyl cyanoacrylate tissue adhesive
Number of subjects: 42
Study 11559213 — intervention group
Group type: COMPARATOR
Intervention: Monofilament suture
Number of subjects: 42
Study 9389845 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% mepivacaine 80 mg
Number of subjects: 200
Study 9389845 — intervention group
Group type: COMPARATOR
Intervention: hyperbaric 0.5% bupivacaine 10 mg
Number of subjects: 200
Study 8178556 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 537
Study 8178556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study 2889303 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg betaxolol
Number of subjects: 0
Study 2889303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29289621 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU/day)
Number of subjects: 0
Study 29289621 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU/day)
Number of subjects: 0
Study 29289621 — intervention group
Group type: COMPARATOR
Intervention: Control group (MDMs differentiated in the absence of vitamin D)
Number of subjects: 0
Study 27115491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (very brief focused attention training)
Number of subjects: 143
Study 27115491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (very brief training)
Number of subjects: 143
Study 27115491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 143
Study 27115491 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 143
Study 27115491 — intervention group
Group type: COMPARATOR
Intervention: Inactive control condition
Number of subjects: 143
Study 25546420 — intervention group
Group type: EXPERIMENTAL
Intervention: MABGEL (2.5 g of gel daily for 12 days containing 10 or 20 mg/g of each mAb)
Number of subjects: 28
Study 25546420 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 28